Abstract Sphingosylphosphorylcholine (SPC) has been implicated in a variety of cellular responses, including proliferation and differentiation. In this study, we demonstrate that D-erythro-SPC, but not L-threo-SPC, stereoselectively stimulated the proliferation of human adipose tissue-derived mesenchymal stem cells (hADSCs), with a maximal increase at 5 mM, and increased the intracellular concentration of Ca 21 ([Ca 21 ] i ) in hADSCs, which do not express known SPC receptors (i.e., OGR1, GPR4, G2A, and GPR12). The SPC-induced proliferation and increase in [Ca 21 ] i were sensitive to pertussis toxin (PTX) and the phospholipase C (PLC) inhibitor U73122, suggesting that PTX-sensitive G proteins, Gi or Go, and PLC are involved in SPC-induced proliferation. In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase ( JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126. Furthermore, the SPC-induced proliferation and JNK activation were completely attenuated by overexpression of a dominant negative mutant of JNK2, and the SPC-induced activation of JNK was inhibited by pretreatment with PTX or U73122. Treatment of hADSCs with lysophosphatidic acid (LPA) receptor antagonist, Ki16425, had no impact on the SPC-induced increase in [Ca 21 ] i . However, SPC-induced proliferation was partially, but significantly, attenuated by pretreatment of the cells with Ki16425. These results indicate that SPC stimulates the proliferation of hADSCs through the Gi/Go-PLC-JNK pathway and that LPA receptors may be responsible in part for the SPC-induced prolifera-
Mesenchymal stem cells can be isolated from a variety of tissues, such as bone marrow, periosteum, trabecular bone, synovium, skeletal muscle, deciduous teeth, and adipose tissues (1) . They possess self-renewal capacity, long-term viability, and differentiation potential toward the diverse cell types, such as adipogenic, osteogenic, chondrogenic, and myogenic lineages (1) (2) (3) (4) (5) (6) . Human adipose tissuederived mesenchymal stem cells (hADSCs) have generated a great deal of interest because of their potential use in clinical applications and their stem cell-like properties. For clinical applications, however, it is necessary to maintain the self-renewal capacity and proliferation of hADSCs during ex vivo amplification of the cells. However, the molecular identities of extracellular agonists and intracellular signaling molecules, which regulate the self-renewal and proliferation of hADSCs, are largely unknown.
Lysophospholipids, such as sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), and sphingosylphosphorylcholine (SPC), play a role in many areas of cellular physiology and pathophysiology (7) (8) (9) (10) . In particular, SPC takes part in several cellular responses, such as migration, wound healing, and differentiation (9, (11) (12) (13) , and is known to stimulate DNA synthesis and proliferation in various cell types, including fibroblasts, endothelial cells, keratinocytes, and vascular smooth muscle cells, as a potent mitogen (9, 12, (14) (15) (16) . In contrast to the above, SPC can also inhibit the growth of various cell types, mostly that of tumor cells such as pancreatic, breast, and ovarian cancer cells and Jurkat T-cells (13, 17) . We recently reported that SPC positively or negatively regulates the proliferation of hADSCs, depending on the concentrations of SPC exposed to hADSCs (18) . However, the molecular mechanism involved in the SPCinduced regulation of proliferation is not clearly understood.
Mitogen-activated protein (MAP) kinases, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, are the major signal transduction molecules regulated by growth factors, cytokines, and stress (19) . Each member of the MAP kinases is activated by phosphorylation and subsequently translocates into the nucleus to promote diverse physiological responses (19) . ERK is mainly activated by growth-promoting factors and participates in cell proliferation or survival, whereas JNK and p38 are mainly activated by stress signals and are known to induce apoptosis in many kinds of cells (19) (20) (21) . Activated JNK phosphorylates serine-63 and serine-73 residues of c-Jun and increases the transcription activity of the AP-1 complex, which is responsible for the transcription of apoptosis-related genes (19) (20) (21) . SPC has been reported to induce the phosphorylation of ERK in several cell types by activation of G protein-coupled receptors (GPCRs) (16, 22, 23) . It has been demonstrated that ERK plays a key role in the SPC-stimulated proliferation of aortic smooth muscle cells (16) and the hypertrophic growth of rat neonatal cardiomyocytes (23) . The SPC-induced activation of ERK and proliferation are mediated by pertussis toxin (PTX)-sensitive G proteins, such as Gi or Go (9, 13) . Recently, we reported that treatment of hADSCs with concentrations of .10 mM SPC induced apoptotic cell death and that the SPC-induced activation of ERK was responsible for the cell death (18) . However, treatment of hADSCs with concentrations of ,5 mM SPC stimulated the proliferation of hADSCs. Therefore, it was not clear which subtypes of MAP kinases were involved in the SPC-induced proliferation of hADSCs. In this study, we demonstrate that SPC is a principal lysophospholipid to stimulate the proliferation of hADSCs and that JNK, but not ERK, plays a crucial role in the SPC-induced proliferation of hADSCs.
MATERIALS AND METHODS

Materials
Minimum essential medium a, phosphate-buffered saline, trypsin, and FBS were purchased from Invitrogen (Carlsbad, CA). SP600125 and 3-(4,5-dimethyl-2-thiozol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were from Calbiochem (La Jolla, CA). U0126, SB202190, and PTX were from Biomol (Plymouth Meeting, PA). S1P, LPC, and LPA were from Avanti Polar Lipids (Alabaster, AL). D-erythro-SPC and L-threo-SPC were from Matreya (Pleasant Gap, PA). Platelet-derived growth factor-BB (PDGF-BB) was purchased from R&D Systems, Inc. (Minneapolis, MN) . The anti-phospho-ERK (Thr202/204), anti-phospho-p38 (Thr180/ Tyr182), and anti-phospho-c-Jun (Ser63) antibodies were from Cell Signaling Technology (Beverly, MA). The anti-ERK antibody was from BD Biosciences (San Diego, CA). Peroxidaselabeled secondary antibodies and the enhanced chemiluminescence kit were purchased from Amersham Biosciences. Collagenase type I, Ki16425, and all other reagents were obtained from Sigma-Aldrich.
Cell culture
Subcutaneous adipose tissue was obtained from elective surgeries with the patients' consent, as approved by the Institutional Review Board, and hADSCs were isolated as reported previously (24) . Briefly, adipose tissues were washed at least three times with sterile phosphate-buffered saline and treated with an equal volume of collagenase type I (1 g/l in Hank's balanced salt solution with 1% BSA) for 60 min at 378C with intermittent shaking. The floating adipocytes were separated from the stromal-vascular fraction by centrifugation (300 g for 5 min). The pellet was resuspended in minimum essential medium a supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin and plated in tissue culture dishes at 3,500 cells/cm 2 . The primary hADSCs were cultured for 4-5 days until confluence and were defined as passage 0. The passage number of hADSCs used in the experiments was 3-10. The expression profiles of the hADSCs were highly similar to those of human bone marrow-derived mesenchymal stem cells, as observed using flow cytometric analysis and microarray analysis (25) . The hADSCs were positive for CD29, CD44, CD90, and CD105, all of which have been reported to be marker proteins of mesenchymal stem cells. However, c-kit, CD34, and CD14, which are known as hematopoietic markers, were not expressed in the hADSCs.
Proliferation assay
Proliferation was determined by both direct counting with a hemocytometer using the trypan blue exclusion method and an indirect colorimetric MTT assay: MTT is metabolized by NADdependent dehydrogenase to form a colored reaction product, and the amount of dye formed directly correlates with the number of cells. For the determination of cell numbers, hADSCs were seeded on a 24-well culture plate at a density of 2 3 10 4 cells/well, cultured for 48 h in the growth medium, serumstarved for 24 h, and then treated with or without various reagents for the indicated times. For the MTT assay, the cells were washed twice with phosphate-buffered saline and incubated with 100 ml of MTT (0.5 mg/ml) for 2 h at 378C. The formazan granules generated by the cells were dissolved in 100 ml of DMSO, and the absorbance of the solution at 562 nm was determined using a PowerWave x microplate spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT) after dilution to a linear range. For direct counting of cell number, the reagenttreated hADSCs were harvested by trypsinization, suspended in phosphate-buffered saline, and incubated with an equal amount of 0.1% trypan blue. The number of trypan blue-negative cells was counted using a hemocytometer. 
Measurement of intracellular calcium concentration
Western blotting
Confluent serum-starved hADSCs were treated under appropriate conditions, washed with ice-cold phosphate-buffered saline, and then lysed in lysis buffer (20 mM Tris-HCl, 1 mM EGTA, 1 mM EDTA, 10 mM NaCl, 0.1 mM phenylmethanesulfonyl fluoride, 1 mM Na 3 VO 4 , 30 mM sodium pyrophosphate, 25 mM b-glycerol phosphate, and 1% Triton X-100, pH 7.4). Lysates were resolved by SDS-PAGE and transferred onto a nitrocellulose membrane. After blocking with 5% nonfat milk, the membranes were immunoblotted with anti-phospho-ERK (Thr202/204), anti-phospho-p38 (Thr180/Tyr182), and anti-ERK at a dilution of 1:1,000. The bound primary antibodies were probed with horseradish peroxidase-conjugated secondary antibodies and visualized by the enhanced chemiluminescence Western blotting system.
JNK activity assay
JNK activity was measured by the glutathione-based pull-down method using a kit from Cell Signaling Technology (Beverly, MA) according to the manufacturer's directions. Briefly, cell extracts (0.2 mg of protein) were incubated with 1 mg of immobilized glutathione-S-transferase-c-Jun(1-79) fusion protein, centrifuged, washed, and incubated in kinase buffer (25 mM TrisHCl, pH 7.5, 5 mM b-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 , and 10 mM ATP) for 30 min at 308C. Phosphorylated substrate was detected by SDS-PAGE and immunoblotting using the phospho-specific c-Jun (Ser63) antibody (dilution, 1:1,000).
Overexpression of dominant negative mutants of JNK2 and MEK1
Recombinant adenoviruses expressing the green fluorescent protein (GFP) or coexpressing GFP and hemagglutinin (HA)-tagged dominant negative mutant of JNK2 (DN-JNK2) have been described (26) . Subconfluent hADSCs were infected with adenoviruses bearing GFP or GFP plus HA-tagged DN-JNK2 at 100-150 plaque-forming units/cell for 1 h. After removing the adenovirus, cells were cultured for an additional 24 h in fresh growth medium. A dominant negative mutant of MEK1 (DN-MEK1) was overexpressed using a retrovirus system as described previously (27) . pMSCVpuro retroviral vector (Clontech, Palo Alto, CA) containing DN-MEK1 was introduced into HEK293T cells (packaging cell line) with 1 mg of pVSV-G vector (Clontech) using the LipofectAMINE Plus reagents according to the instructions from the manufacturer. The next day, virus supernatant from these cells was added with 5 mg/ml Polybrene to hADSCs. After 24 h of incubation, the medium was replaced with fresh medium. The expression levels of DN-JNK2 and DN-MEK1 were determined by Western blotting with anti-HA antibody.
RT-PCR analysis
mRNA was isolated using a QIAshredder and an RNeasy kit (Qiagen, Hilden, Germany). mRNA, Moloney murine leukemia virus reverse transcriptase, and pd(N)6 primers (GIBCO BRL, Gaithersburg, MD) were used to obtain cDNA. The primers used for the RT-PCR analysis have been reported previously (28) . The sequences of the primers used were as follows; LPA 1 receptor (349 bp product): sense, 59-TCTTCTGGGCCATTTTCAAC-39; antisense, 59-TGCCTRAAGGTGGCGCTCAT-39. LPA 2 receptor (798 bp product): sense, 59-CCTACCTCTTCCTCATGTTC-39; antisense, 59-TAAAGGGTGGAGTCCATCAG-39. LPA 3 receptor (382 bp product): sense, 59-GGAATTGCCTCTGCAACATCT-39; antisense, 59-GAGTAGATGATGGGGTTCA-39. GAPDH (246 bp product): sense, 59-GATGACATCAAGAAGGTGGTGAA-39, antisense, 59-GTCTTACTCCTTGGAGGCCATGT-39. We ran 30 PCR cycles of 948C (denaturation, 1 min), 558C (annealing, 1 min), and 728C (extension, 1 min). PCR products were electrophoresed on a 2% agarose gel and visualized by ethidium bromide staining.
RESULTS
SPC induces the proliferation of human hADSCs
We measured the proliferation of hADSCs by the MTT assay method after treatment of the cells with the indicated concentrations of lysophospholipids for 48 h. As shown in Fig. 1A , treatment of hADSCs with D-erythro-SPC, a naturally occurring stereoisomer of SPC, stimulated proliferation at 50 nM and dose-dependently increased the proliferation with a maximal peak at 5 mM. However, concentrations of D-erythro-SPC of .10 mM caused apoptotic cell death, as demonstrated previously (18) . Exposure of hADSCs to LPA and LPC also induced proliferation, with maximal stimulation at 2 and 5 mM, respectively. Nevertheless, the stimulatory effects of both LPA and LPC were less than that of D-erythro-SPC, and S1P had no effect on the proliferation of hADSCs. hADSCs exhibited fibroblast-like morphologies and slowly proliferated in the absence of exogenous SPC, whereas treatment of the cells with 5 mM D-erythro-SPC drastically increased the cell number in a time-dependent manner (Fig. 1B, C) . The Derythro-SPC-induced increase in cell numbers was comparable to the increase mediated by PDGF-BB, which is known as a potent mitogen in mesenchymal cell types (29) , although the SPC-or PDGF-induced proliferation was less potent than the increase induced by 10% FBS (Fig. 1B,  C) . These results suggest that not only PDGF-BB but also SPC is a potent mitogen stimulating the proliferation of hADSCs in the absence of FBS. (Fig. 3B) . Consistent with these results, SPC-induced proliferation was completely prevented by pretreatment with either PTX or U73122 (Fig. 3C) . These results suggest that Gi/Go-and PLC-dependent pathways are involved 
SPC stereoselectively increases intracellular
JNK is involved in the SPC-induced proliferation of hADSCs
To explore whether SPC induces the activation of MAP kinases, we measured the effect of exogenous SPC on JNK activity and the phosphorylation of ERK and p38 MAP kinases. JNK activity was determined by measuring the JNKdependent phosphorylation of c-Jun, as described in Materials and Methods. Phosphorylation of c-Jun occurred in response to treatment with 5 mM D-erythro-SPC for 10 min, and the SPC-induced phosphorylation of c-Jun at serine-63 was completely abolished by pretreatment with SP600125, a JNK-specific inhibitor, but not with either U0126 or SB202190 (Fig. 4A, B) . These results suggest that the SPCinduced phosphorylation of c-Jun is dependent specifically on JNK activation. In addition, SPC treatment induced the phosphorylation of ERK, which could be completely prevented by pretreatment with U0126, a MEK-specific inhibitor, but not with SP600125 or SB202190 (Fig. 4C) . Treatment of the cells with SPC did not induce the phosphorylation of p38, although phosphorylation of both p38 and JNK was highly stimulated by treatment with anisomycin, which is well known to stimulate JNK and p38 (31).
These results indicate that SPC induces the activation of JNK and ERK in hADSCs and that SP600125 and U0126 specifically block the SPC-induced activation of JNK and ERK, respectively. To clarify whether MAP kinases are involved in SPC-induced proliferation, we examined the effect of MAP kinase inhibitors on the proliferation of hADSCs. As shown in Fig. 4D , pretreatment of the cells with SP600125 completely attenuated SPC-induced proliferation, whereas pretreatment with U0126 or SB202190 had little impact on SPC-induced proliferation, suggesting that JNK, but not ERK or p38, is primarily involved in SPC-induced proliferation.
DN-JNK2 blocks the SPC-induced proliferation of hADSCs
To further confirm the finding that JNK is involved in the SPC-induced proliferation of hADSCs, we next explored the effects of DN-JNK2 on the SPC-induced proliferation and phosphorylation of c-Jun. Adenoviral expression of DN-JNK2 has been reported to specifically block JNK-dependent signaling (26); therefore, HA-tagged DN-JNK2 and GFP were coexpressed in hADSCs by the adenovirus system. Figure 5A shows that infection of adenoviruses expressing GFP or coexpressing GFP and HA-tagged DN-JNK2 elicited the expression of GFP in most hADSCs, as judged by fluorescence microscopy. As shown in Fig. 5B , the expression of HA-tagged DN-JNK2 was determined by Western blotting with anti-HA antibody. Next, to explore whether the DN-JNK2 blocked the SPC-induced phosphorylation of c-Jun, we measured the JNK activity in the hADSCs infected with HA-tagged DN-JNK2. In the GFP-expressing hADSCs, SPC treatment induced the phosphorylation of c-Jun. However, coexpression of GFP and HA-tagged DN-JNK2 completely attenuated the SPC-induced phosphorylation of c-Jun (Fig. 5C ). These results led us to conclude that overexpression of DN-JNK2 can abrogate the SPCinduced activation of JNK in hADSCs.
To confirm the contention that JNK plays a crucial role in the SPC-induced proliferation of hADSCs, we next explored the effects of DN-JNK2 on SPC-induced proliferation. As shown in Fig. 5D , SPC increased the proliferation of hADSCs infected with adenovirus bearing GFP, used as a control. However, adenoviral overexpession of HA-tagged DN-JNK2 blocked SPC-induced proliferation, which was determined by MTT assay.
To further explore whether the MEK-ERK pathway is involved in SPC-induced proliferation, we examined the effects of DN-MEK1 on the SPC-induced proliferation and activation of ERK. As shown in Fig. 5E , overexpression of DN-MEK1 inhibited the SPC-induced phosphorylation of ERK. However, overexpression of DN-MEK1 could not attenuate the SPC-induced proliferation in hADSCs (Fig. 5F ). Together, these results indicate that JNK, but not ERK, plays a pivotal role in SPC-induced proliferation.
SPC activates JNK through PTX-sensitive and PLC-dependent pathways
It has been reported that the SPC-induced activation of ERK is mediated by Gi/Go-dependent activation of PLC (9, 13, 16, 22) . Because SPC-induced proliferation required the activation of Gi/Go, PLC, and JNK, we next explored whether the SPC-induced activation of JNK was dependent on Gi/Go and PLC. Pretreatment of hADSCs with either PTX or U73122 significantly attenuated the SPC-induced activation of JNK (Fig. 6A, B) . These results suggest that the SPC-induced activation of JNK, which occurs through the Gi/Go-PLC pathway, plays an important role in the SPC-induced proliferation of hADSCs.
Partial involvement of LPA receptors in SPC-induced proliferation
Lysophospholipid-induced physiological responses occurred by the activation of PTX-sensitive G proteins, Gi or Go, in a variety of cell types (32) (33) (34) (35) . Recently, the Gi/ Go-JNK pathway has been reported to play a role in the LPA-induced migration of glioma cells (32) . In this study, we demonstrated that LPA as well as SPC stimulates the proliferation of hADSCs, although the stimulatory effects of LPA were less potent than those of SPC. Using RT-PCR analysis, we observed that three LPA receptors, LPA 1 , LPA 2 , and LPA 3 , are expressed in hADSCs (Fig. 7A) . Therefore, we sought to examine whether the SPC-induced proliferation is mediated by the activation of LPA receptors. To determine whether the LPA receptors mediate SPC-induced signal transduction, we examined the effects of Ki16425, an antagonist for LPA 1 (Fig. 7C) . In contrast, the SPC-induced increase in [Ca 21 ] i was not affected by pretreatment of the cells with Ki16425 (Fig. 7D) . These results suggest that LPA receptors are not involved in the SPC-induced increase in [Ca 21 ] i and do not serve as SPC receptors. To explore whether the SPC-induced proliferation of hADSCs requires the activation of LPA receptors, we next examined the effects of Ki16425 on SPC-induced proliferation. As shown in Fig. 7E , treatment ] i . These results indicate that the SPC-induced increase in [Ca 21 ] i and proliferation of hADSCs may require the Gi/Go-coupled receptor-dependent activation of PLC. Furthermore, we demonstrated that the Gi/Go-PLC-dependent activation of JNK is also required for the SPC-induced proliferation of hADSCs. A lot of different GPCRs were shown to activate JNK; however, the underlying mechanisms are still poorly understood (33, 36) . It has been reported that Ga i2 and Gbg subunits released from Gabg complexes upon stimulation of GPCRs are involved in the activation of JNK (33, 37) and that a variety of signaling enzymes, including PLC, PKC, Pyk2, focal adhesion kinases, and diverse GEFs for Rho family GTPases, are implicated in the G protein subunit-mediated activation of JNK (33, 36) . These results support the The densities of p-c-Jun and GST-c-Jun were quantified from three independent experiments, and the phosphorylation levels of c-Jun were normalized to the amounts of GST-c-Jun in the samples. The data are presented as percentages of controls (mock-treated cells) and expressed as means 6 SEM of three independent experiments. C: Phosphorylation of extracellular signalregulated kinase (ERK) and p38 was probed by Western blotting of the cell lysates with anti-phospho-ERK and anti-phospho-p38 antibodies, respectively, and the amounts of ERK were probed by anti-ERK antibody to confirm equal loading. Data are representative of three independent experiments. D: hADSCs were serum-starved for 24 h, pretreated with vehicle (solid line; 0.1% DMSO), 10 mM U0126, 10 mM SP600125 (SP), or 10 mM SB202190 (SB) for 15 min at 378C, and then exposed to 5 mM D-erythro-SPC for 48 h. Proliferation was probed by the MTT assay. Results are expressed as percentages of vehicle-treated controls. Data are shown as means 6 SEM (n 5 4) and are representative of three independent experiments. * P , 0.05 by Student's t-test.
SPC-induced proliferation of mesenchymal stem cellspresent study, suggesting that Ga i and/or Gbg play a crucial role in SPC-induced proliferation through the activation of PLC and JNK in hADSCs. Further studies concerning the molecular mechanism of the PLC-mediated activation of JNK would provide more detailed understanding of SPC-induced proliferation.
Several GPCRs, such as OGR1, GPR4, G2A, and GPR12, were recently identified as high-affinity receptors for SPC (9, 13). However, we observed that these SPC receptors were not expressed in hADSCs, when examined by RT-PCR (18) . Furthermore, recent accumulating evidence demonstrates that OGR1, GPR4, and G2A are activated by proton but not by SPC (38) (39) (40) . These results suggest that the SPC-induced proliferation and increase in [Ca 21 ] i may not be dependent on these known SPC receptors. Several reports have provided evidence to indicate that S1P receptors act as low-affinity receptors for SPC (9, 13) . However, in contrast to SPC-stimulated proliferation, we demonstrate here that S1P had no impact on the proliferation of hADSCs (Fig. 1A) . We demonstrate that the inhibition of LPA 1 and LPA 3 by Ki16425 treatment significantly abrogated any LPA-induced increase in [Ca 21 ] i , in contrast to the lack of impact on the SPC-induced increase of [Ca 21 ] i . These results suggest that SPC-induced proliferation is partially mediated by the activation of LPA receptors (i.e., LPA 1 and/or LPA 3 ), whereas the LPA receptors are not likely to serve as SPC receptors (Fig. 7) . A possible explanation for the implication of LPA receptors in SPC-induced proliferation is that treatment of hADSCs with SPC for 2 days may elicit the production of LPA, and the subsequent activation of LPA 1 or LPA 3 by the released LPA may play a role in the SPC-induced proliferation (Fig. 8) .
To prove this possibility, it should be clarified whether LPA can be produced by SPC treatment, and the molecular mechanisms involved in the SPC-induced production of LPA need to be explored further, because diverse enzymes, including autotoxin, phospholipase A 2 , and phospholipase D, have been implicated in LPA production (41, 42) . In addition, the involvement of the Gi/Go-PLC-JNK pathway in the LPA receptor-mediated indirect pathway (Fig. 8 ) needs to be determined further. In spite of a crucial role of LPA receptors in SPC-induced proliferation, Ki16425 treatment could not completely prevent SPC-induced proliferation. These results suggest that SPCinduced proliferation may be mediated in part by the activation of unidentified SPC receptors (Fig. 8) . Another possibility is that LPA 2 may be responsible for the Ki16425-independent proliferation of hADSCs in response to SPC treatment, because Ki16425 is an antagonist specific for LPA 1 and LPA 3 . To clarify these contentions, it is necessary to confirm the involvement of the LPA receptors in SPCinduced proliferation by RNA interference technology.
SPC has been shown to induce the activation of ERK in a variety of cell types (13, 22) . In this study, we demonstrate for the first time that not only ERK but also JNK was activated by SPC treatment and that JNK plays a major role in the SPC-induced proliferation of hADSCs. Pharmacological inhibition of JNK activation or overexpression of DN-JNK2 attenuated the SPC-induced proliferation of hADSCs, whereas inhibition of ERK had only a marginal effect on PDGF-induced proliferation. In contrast, we demonstrate that cell death caused by treatment of hADSCs with high concentrations of SPC could be completely prevented by inhibition of ERK but not by JNK inhibition (18) . These results appear to be contradictory to previous findings that ERK and JNK play a key role in growth factor-induced proliferation and in stress-induced apoptosis, respectively (19) , and that ERK is involved in SPC-induced proliferation in aortic smooth muscle cells (16) . Nevertheless, recent accumulating evidence suggests that JNK plays a key role in cell survival and the proliferation of various cell types (20, 43) . Inhibition of basal JNK activity by SP600125 or antisense oligonucleotides attenuated the proliferation of KB-3 human carcinoma cells (44) , and SP600125 inhibited cyclin D1 expression and proliferation during liver regeneration (45) . Furthermore, both overexpression of a dominant negative mutant of JNK and the pharmacological inhibition of JNK blocked the PDGF-induced proliferation of smooth muscle cells (46, 47) . Consistent with these findings, we also observed that PDGF as well as SPC stimulated the proliferation of hADSCs by a JNK-dependent pathway (48) , and several recent studies demonstrated that the MEK-ERKdependent pathway plays a key role in the induction of apoptosis (49) (50) (51) (52) . Therefore, these results support our conclusion that JNK, but not ERK, plays a crucial role in the SPCinduced proliferation of hADSCs.
By means of matrix-assisted laser desorption ionization time-of-flight mass spectrometry, the concentration of SPC was estimated at 50 nM in plasma and 130 nM in serum (53) . We observed that proliferation of hADSCs was significantly increased in response to 50 nM SPC and dosedependently stimulated, with a maximal increase at 5 mM SPC (Fig. 1A) . It has been reported that SPC induces proliferation in the micromolar range up to 10 mM in several other cell types (15, 54) . Because these concentration of SPC are higher than that found in plasma (53), the physiological relevance of the SPC-induced proliferation can be argued. SPC is unlikely to act as a hormone but rather as a paracrine mediator in local microenvironments. Furthermore, SPC is concentrated within lipoprotein particles, such as high density lipoproteins (55, 56) . Therefore, the concentration of SPC in local microenvironments could not be clearly determined. Although the physiological relevance of SPC-induced proliferation has not been clarified, the stimulatory effect of SPC on the proliferation of hADSCs was almost comparable to that of PDGF-BB, which is a potent mitogen for mesenchymal cell types. This result raised the possibility that SPC may be useful for the in vitro amplification of hADSCs because of the immunogenic properties of FBS. However, the stimulatory effect of SPC on proliferation was not completely equivalent to the growth-promoting activity of 10% FBS. Therefore, combined treatment of SPC with other growth factors may be needed for the optimal amplification of hADSCs in vitro. The physiological significance of the SPC-induced proliferation of hADSCs within adipose tissues and the effects of SPC on the differentiation of hADSCs should be clarified further.
